Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
D 110.44 1.99% 2.15
NBIX closed up 0.04 percent on Monday, January 30, 2023, on 1.2 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Feb 9
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 1.59%
Oversold Stochastic Weakness 1.59%
NR7 Range Contraction 1.63%
Narrow Range Bar Range Contraction 1.63%
Oversold Stochastic Weakness 1.63%
Outside Day Range Expansion 1.50%
Oversold Stochastic Weakness 1.50%
NR7 Range Contraction 1.11%
Narrow Range Bar Range Contraction 1.11%
Oversold Stochastic Weakness 1.11%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 5 hours ago
Rose Above Previous Day's High about 6 hours ago
Up 1% about 6 hours ago
10 DMA Resistance about 6 hours ago
Rose Above 10 DMA about 6 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Neurocrine Biosciences, Inc. Description

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Pain Alcohol Diabetes Disorders Cardiovascular Disease Schizophrenia Vascular Disease Epilepsy Hormones Ethers Movement Disorders Insomnia Transporter I Diabetes Boehringer Ingelheim Endometriosis Fibroids Ii Diabetes Essential Tremor Gnrh Antagonists Pyrimidines Uterine Fibroid Dyskinesia Gonadotropin Releasing Hormone Antagonist Neurocrine Biosciences

Is NBIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 129.23
52 Week Low 75.27
Average Volume 716,610
200-Day Moving Average 104.67
50-Day Moving Average 116.94
20-Day Moving Average 112.13
10-Day Moving Average 108.94
Average True Range 2.93
RSI 37.11
ADX 23.58
+DI 13.50
-DI 23.94
Chandelier Exit (Long, 3 ATRs) 116.22
Chandelier Exit (Short, 3 ATRs) 115.03
Upper Bollinger Bands 122.91
Lower Bollinger Band 101.34
Percent B (%b) 0.32
BandWidth 19.24
MACD Line -2.69
MACD Signal Line -2.58
MACD Histogram -0.1097
Fundamentals Value
Market Cap 10.12 Billion
Num Shares 93.4 Million
EPS 0.96
Price-to-Earnings (P/E) Ratio 112.45
Price-to-Sales 8.97
Price-to-Book 11.10
PEG Ratio 1.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.02
Resistance 3 (R3) 111.06 110.19 110.56
Resistance 2 (R2) 110.19 109.49 110.17 110.41
Resistance 1 (R1) 109.24 109.06 108.80 109.20 110.26
Pivot Point 108.37 108.37 108.15 108.35 108.37
Support 1 (S1) 107.42 107.67 106.99 107.38 106.32
Support 2 (S2) 106.55 107.25 106.53 106.17
Support 3 (S3) 105.60 106.55 106.02
Support 4 (S4) 105.56